AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10427881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg i.m.
Number of subjects: 48
Study 10427881 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 1 mg/kg s.c.
Number of subjects: 48
Study 7579506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/day for 2 years
Number of subjects: 370
Study 7579506 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant hormone therapy
Number of subjects: 370
Study 7579506 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 370
Study 2223432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (calcium antagonist)
Number of subjects: 0
Study 2223432 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 7209768 — intervention group
Group type: COMPARATOR
Intervention: Ignore acid group - Proximal gastric vagotomy
Number of subjects: 0
Study 7209768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored group - Proximal gastric vagotomy if peak acid output < 40 mEq/hr; Vagotomy and antrectomy if peak acid output > 40 mEq/hr
Number of subjects: 0
Study 7209768 — intervention group
Group type: COMPARATOR
Intervention: Ignore acid group - Peak acid output > 40 mEq/hr
Number of subjects: 0
Study 7209768 — intervention group
Group type: COMPARATOR
Intervention: Ignore acid group - Peak acid output < 40 mEq/hr
Number of subjects: 0
Study 7209768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored group - Vagotomy plus antrectomy
Number of subjects: 0
Study 7209768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored group - Proximal gastric vagotomy
Number of subjects: 0
Study 30717365 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related information
Number of subjects: 205
Study 30717365 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on bitterness-taste
Number of subjects: 205
Study 28865313 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group (participants could choose the order of hands for trials)
Number of subjects: 0
Study 28865313 — intervention group
Group type: COMPARATOR
Intervention: Control group (hand order determined by choice-group counterparts)
Number of subjects: 0
Study 26923512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber composite (FC) ingredient in a smoothie-type beverage
Number of subjects: 0
Study 26923512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber composite (FC) ingredient in a cold-pressed snack bar
Number of subjects: 0
Study 26923512 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (MD)
Number of subjects: 0
Study 23800503 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure control
Number of subjects: 3020
Study 23800503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 3020
Study 23800503 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 3020
Study 22228638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg twice daily plus temsirolimus 25 mg weekly (Arm A)
Number of subjects: 102
Study 22228638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg every morning, 200 mg every night plus tipifarnib 100 mg twice daily (Arm B)
Number of subjects: 102
Study 21187625 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft with Cyclosporine-A (CsA)
Number of subjects: 15
Study 21187625 — intervention group
Group type: COMPARATOR
Intervention: Control site (Allograft alone)
Number of subjects: 15
Study 17928091 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: rapid tapering and withdrawal 91 days after LT
Number of subjects: 39
Study 17928091 — intervention group
Group type: COMPARATOR
Intervention: Group B: slow tapering and withdrawal 25 months after LT
Number of subjects: 39
Study 16532676 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C status in asthmatic patients
Number of subjects: 100
Study 16532676 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study 16532676 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of asthma
Number of subjects: 100
Study 11823112 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg/day
Number of subjects: 324
Study 11823112 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 2000 mg/day
Number of subjects: 324
Study 11823112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 9579769 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (0.25 to 16 mg/day)
Number of subjects: 322
Study 9579769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 9579769 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 322
Study 7666079 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin and hydrocortisone (cohort A: loading dose followed by continuous infusion)
Number of subjects: 56
Study 7666079 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin and hydrocortisone (cohort B: intermittent schedule)
Number of subjects: 56
Study 7666079 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin and hydrocortisone (cohort C: empiric dosing regimen)
Number of subjects: 56
Study 7666079 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin and hydrocortisone (all cohorts)
Number of subjects: 56
Study 7666079 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin and hydrocortisone (sequential regimens)
Number of subjects: 56
Study 2572047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine treatment
Number of subjects: 8
Study 2572047 — intervention group
Group type: COMPARATOR
Intervention: Salicylazosulfapyridine (SASP) treatment
Number of subjects: 8
Study 598403 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0
Study 598403 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 598403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31186389 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercises for 60 minutes, two times a week for six months, in addition to standard medical care.
Number of subjects: 32
Study 31186389 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care with no change in regular daily activities.
Number of subjects: 32
Study 29066877 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous teriparatide (20 μg/day)
Number of subjects: 362
Study 29066877 — intervention group
Group type: COMPARATOR
Intervention: Intranasal salmon calcitonin (200 IU/day)
Number of subjects: 362
Study 24373198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp scratch
Number of subjects: 192
Study 24373198 — intervention group
Group type: COMPARATOR
Intervention: Ready?
Number of subjects: 192
Study 23989999 — intervention group
Group type: EXPERIMENTAL
Intervention: PESA-IVF + RE-ICSI
Number of subjects: 20
Study 23989999 — intervention group
Group type: COMPARATOR
Intervention: PESA-ICSI
Number of subjects: 20
Study 21676992 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of lurasidone
Number of subjects: 0
Study 21676992 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of lurasidone
Number of subjects: 0
Study 21676992 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of olanzapine
Number of subjects: 0
Study 21676992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21676992 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined lurasidone groups
Number of subjects: 0
Study 21676992 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 20112596 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day elemental zinc
Number of subjects: 68
Study 20112596 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 68
Study 16786405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nullification instructions in a nullification-relevant trial (murder for profit vs. euthanasia)
Number of subjects: 0
Study 16786405 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional biases
Number of subjects: 0
Study 16786405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nullification instructions
Number of subjects: 0
Study 15219483 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (n = 12)
Number of subjects: 24
Study 15219483 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior partial fundoplication (n = 12)
Number of subjects: 24
Study 11490185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair shave
Number of subjects: 90
Study 11490185 — intervention group
Group type: COMPARATOR
Intervention: No hair shave
Number of subjects: 90
Study 9129883 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 3141
Study 9129883 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilating beta-blockers (e.g., carvedilol)
Number of subjects: 3141
Study 9129883 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard beta-blockers (e.g., metoprolol)
Number of subjects: 3141
Study 8499737 — intervention group
Group type: EXPERIMENTAL
Intervention: HDivIg at 500 mg/kg given over 2 h
Number of subjects: 34
Study 8499737 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment including phototherapy
Number of subjects: 34
Study 3677213 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA (1300 mg) alone
Number of subjects: 10
Study 3677213 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA (1300 mg) plus Ranitidine (150 mg)
Number of subjects: 10
Study 3677213 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 10
Study 31879812 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg intravenous tranexamic acid (IV-TXA) before incision (Group B)
Number of subjects: 132
Study 31879812 — intervention group
Group type: COMPARATOR
Intervention: 20 mg/kg intravenous tranexamic acid (IV-TXA) before incision (Group A)
Number of subjects: 132
Study 31879812 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg intravenous tranexamic acid (IV-TXA)
Number of subjects: 132
Study 29936239 — intervention group
Group type: EXPERIMENTAL
Intervention: G-ICBT
Number of subjects: 132
Study 29936239 — intervention group
Group type: EXPERIMENTAL
Intervention: U-ICBT
Number of subjects: 132
Study 29936239 — intervention group
Group type: EXPERIMENTAL
Intervention: BIB-CBT
Number of subjects: 132
Study 29936239 — intervention group
Group type: COMPARATOR
Intervention: WLC
Number of subjects: 132
Study 27481016 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide and 50% oxygen (N2O/O2)
Number of subjects: 80
Study 27481016 — intervention group
Group type: COMPARATOR
Intervention: Oxygen (O2)
Number of subjects: 80
Study 27481016 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O/O2
Number of subjects: 80
Study 27481016 — intervention group
Group type: COMPARATOR
Intervention: O2
Number of subjects: 80
Study 23530708 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 10
Study 23530708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22968662 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal radius bone graft (group 1)
Number of subjects: 100
Study 22968662 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone graft (group 2)
Number of subjects: 100
Study 22968662 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 100
Study 20446013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 276
Study 20446013 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 276
Study 18557720 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-690 550 15 mg BID
Number of subjects: 28
Study 18557720 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-690 550 30 mg BID
Number of subjects: 28
Study 18557720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 16429938 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin
Number of subjects: 50
Study 16429938 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 50
Study 15303108 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle education group (LE‐G)
Number of subjects: 90
Study 15303108 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitutional diet with guided physical activity (SD/PA‐G)
Number of subjects: 90
Study 15303108 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitutional diet without guided physical activity (SD‐G)
Number of subjects: 90
Study 11765071 — intervention group
Group type: EXPERIMENTAL
Intervention: Na sucrose octasulfate (Na SOS)
Number of subjects: 60
Study 11765071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9266888 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI albuterol (360 microg)
Number of subjects: 11
Study 9266888 — intervention group
Group type: COMPARATOR
Intervention: NEB albuterol (1.5 mg)
Number of subjects: 11
Study 9266888 — intervention group
Group type: COMPARATOR
Intervention: MDI saline solution placebo
Number of subjects: 11
Study 9266888 — intervention group
Group type: COMPARATOR
Intervention: NEB saline solution placebo
Number of subjects: 11
Study 8418345 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcomputer workstations for writing all inpatient orders
Number of subjects: 5219
Study 3521619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried garlic (3 X 198 mg) in Study I
Number of subjects: 85
Study 3521619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried garlic (3 X 450 mg) in Study II
Number of subjects: 85
Study 3521619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 30683623 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of autogenous and xenogenous bone
Number of subjects: 10
Study 30683623 — intervention group
Group type: COMPARATOR
Intervention: Sinus membrane elevation without using any substitutes
Number of subjects: 10
Study 28476062 — intervention group
Group type: EXPERIMENTAL
Intervention: Single radius (SR) TKR
Number of subjects: 105
Study 28476062 — intervention group
Group type: COMPARATOR
Intervention: Multiple radius (MR) TKR
Number of subjects: 105
Study 26802112 — intervention group
Group type: EXPERIMENTAL
Intervention: MI+Education
Number of subjects: 330
Study 26802112 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 330
Study 23246060 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation technique (CO2 group, n = 10)
Number of subjects: 20
Study 23246060 — intervention group
Group type: COMPARATOR
Intervention: Lund technique without CO2 insufflation (Lund group, n = 10)
Number of subjects: 20
Study 22932944 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-laryngoscopy (VL)
Number of subjects: 40
Study 22932944 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 40
Study 22932944 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (VL and DL)
Number of subjects: 40
Study 20399409 — intervention group
Group type: EXPERIMENTAL
Intervention: WIC-based intervention
Number of subjects: 0
Study 20399409 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17646564 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (350 mg single dose)
Number of subjects: 16
Study 17646564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14732423 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency of swallowing tobacco juice
Number of subjects: 68
Study 14732423 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum nicotine concentrations
Number of subjects: 68
Study 12526280 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40-80 mg
Number of subjects: 522
Study 12526280 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10-20 mg
Number of subjects: 522
Study 9815865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoteplase (15, 30, 60, or 120 kU/kg)
Number of subjects: 602
Study 9815865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoteplase (120 kU/kg)
Number of subjects: 602
Study 9815865 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 602
Study 9815865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanoteplase
Number of subjects: 602
Study 7694975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole 2 g by intravenous push immediately prior to incision
Number of subjects: 12
Study 7694975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole 2 g by intravenous push 15 to 60 minutes prior to incision
Number of subjects: 12
Study 2566222 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA treatment
Number of subjects: 0
Study 2566222 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB treatment
Number of subjects: 0
Study 2566222 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed control (one hand)
Number of subjects: 0
Study 1209435 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of vitamins B6, B1 and B12
Number of subjects: 96
Study 1209435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 31229593 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular point‐of‐care test (POCT) for viral and atypical pathogens plus routine real‐time PCR
Number of subjects: 800
Study 28649870 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dosing of 10 ml radiolabeled Wet® Original® lubricant
Number of subjects: 5
Study 28649870 — intervention group
Group type: COMPARATOR
Intervention: Applicator dosing of 10 ml radiolabeled hydroxyethyl cellulose universal placebo gel
Number of subjects: 5
Study 28649870 — intervention group
Group type: COMPARATOR
Intervention: Applicator dosing of 3.5 ml radiolabeled hydroxyethyl cellulose universal placebo gel
Number of subjects: 5
Study 24782286 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg pethidine
Number of subjects: 600
Study 24782286 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 μg/kg sufentanil
Number of subjects: 600
Study 24782286 — intervention group
Group type: COMPARATOR
Intervention: Both groups (pethidine and sufentanil)
Number of subjects: 600
Study 23148048 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g of vegetables and 25 mL PUFA-rich plant oil per day
Number of subjects: 76
Study 23148048 — intervention group
Group type: COMPARATOR
Intervention: Information about the benefits of a healthy diet
Number of subjects: 76
Study 23148048 — intervention group
Group type: COMPARATOR
Intervention: Control group (information only)
Number of subjects: 76
Study 23148048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (vegetables and PUFA-rich oil)
Number of subjects: 76
Study 21616014 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care biochemical marker panel
Number of subjects: 2263
Study 21616014 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2263
Study 19185463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 42
Study 19185463 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 42
Study 17975459 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-free crutch
Number of subjects: 80
Study 15585732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 257
Study 15585732 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stent
Number of subjects: 257
Study 12575566 — intervention group
Group type: EXPERIMENTAL
Intervention: Baisuifang Oral Liquid (BSF)
Number of subjects: 65
Study 12575566 — intervention group
Group type: COMPARATOR
Intervention: Naofukang (Control)
Number of subjects: 65
Study 9622267 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol beer (0.9%, v/v)
Number of subjects: 55
Study 9622267 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-strength beer (5%, v/v)
Number of subjects: 55
Study 7946935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg three times daily)
Number of subjects: 24
Study 7946935 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg once daily)
Number of subjects: 24
Study 7946935 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Nimodipine and Diazepam)
Number of subjects: 24
Study 3062266 — intervention group
Group type: EXPERIMENTAL
Intervention: biosynthetic human proinsulin
Number of subjects: 18
Study 3062266 — intervention group
Group type: COMPARATOR
Intervention: biosynthetic human NPH insulin (controls)
Number of subjects: 18
Study 31937906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration <6 hours
Number of subjects: 1202
Study 31937906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration 8–<9 hours
Number of subjects: 1202
Study 31937906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 1202
Study 31937906 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss history
Number of subjects: 1202
Study 31162192 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraventricular drainage plus intraventricular alteplase
Number of subjects: 499
Study 31162192 — intervention group
Group type: COMPARATOR
Intervention: Extraventricular drainage plus saline
Number of subjects: 499
Study 28675814 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to violence from teachers
Number of subjects: 3706
Study 28675814 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to caregiver violence
Number of subjects: 3706
Study 28675814 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to intimate partner violence (IPV) against female caregivers
Number of subjects: 3706
Study 28675814 — intervention group
Group type: EXPERIMENTAL
Intervention: All violence measures
Number of subjects: 3706
Study 25581701 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive coping strategies (e.g., problem solving, cognitive reframing)
Number of subjects: 645
Study 25581701 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative coping strategies (e.g., fighting, breaking things)
Number of subjects: 645
Study 22914101 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance spectroscopy (BIS)
Number of subjects: 79
Study 22914101 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected arm muscle area (CAMA)
Number of subjects: 79